Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC deal
One of Shanda’s portfolio companies, the digital treatment developer Pear Therapeutics, is taking the SPAC track, going public through a deal expected to provide about $400 million in new funding as the company looks to expand its prescription apps to a wider range of conditions.
Those proceeds include $125 million gathered from private investments in Pear’s newfound public equity, plus $276 million held by Thimble Point Acquisition Corp., a blank-check company backed by the Pritzker Vlock Family Office, whose investment portfolio spans several medtech and biotech companies.
Photo credit: Getty Images
You might also interested in
-
WhizAI Closes New Round with Investment from Shanda Group and AmerisourceBergen Bringing Total Capital Raised to $21 Million
SOMERSET, N.J.–(BUSINESS WIRE)–WhizAI, the first and only augmented analytics platform purpose built for the life sciences and healthcare industries, has […] -
Foundation Capital Invests in Vibe Capital, a New Venture Firm Built for Scrappy International Founders
Limited partners in Vibe Capital include Bessemer Venture Partners, Tribe Capital and Foundation Capital, as well as individuals including GSV […] -
Hustle Fund Raises $33.6 Million To Democratize Access To Pre-Seed Capital
Shanda Group was happy to “re-up” for Hustle Fund’s second fund, which is about three times larger than its first. […]